Masitinib Sales Forecast

Key Factors Driving Masitinib Growth

Broad Clinical Development Across Multiple Diseases

AB Science is conducting confirmatory Phase III trials for masitinib in ALS, multiple sclerosis, and prostate cancer, with regulatory authorization from both the FDA and EMA for key studies. Positive peer-reviewed publications highlight masitinib’s potential efficacy in Alzheimer’s disease, expanding its neurodegenerative footprint.

A recent press release announced identification of a plasma biomarker to predict response in ALS and other CNS diseases - potentially aiding regulatory alignment and patient selection. Multiple large indications substantially increase the total addressable opportunity for masitinib well beyond a single disease.

Strong Intellectual Property Position

AB Science continues extending patent protections for masitinib across key indications with long exclusivity timelines:

Progressive MS protection in Japan until 2041 - potentially first in class for this unmet form of MS. Patents for ALS, Alzheimer’s, sickle-cell disease, prostate cancer and more with protection extending into the late 2030s/early 2040s. Extended patents improve the long-term commercial runway, justifying investment in large-scale Phase III programs.

Regulatory Engagement and Clinical Data Momentum

The confirmatory Phase III trial in ALS has been authorized in multiple European countries and the US - a critical step toward potential registration. Phase III confirmatory study authorized by the FDA and EMA in metastatic prostate cancer augments masitinib’s potential in oncology.

Regulatory momentum - particularly alignment with both US and EU agencies - de-risks the timeline toward potential commercialization.

Scientific Differentiation & Biomarker Strategy

Potential biomarker-driven patient selection could improve responder rates and increase the likelihood of successful approvals, a notable advantage in neurodegenerative disease development.

Masitinib Recent Developments

• ·       In February 2026, AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS).
• ·       In January 2026, AB Science received a patent in Japan covering the use of its investigational oral therapy masitinib for progressive forms of multiple sclerosis (MS). The new patent - JP 7788154 - grants the France-based pharmaceutical company protection in the Asian nation through February 2041 on the use of masitinib for both primary progressive MS (PPMS) and nonactive secondary progressive MS (SPMS).

“Masitinib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Masitinib for potential indication like Alzheimer’s disease, Asthma, Colorectal cancer, Gastrointestinal stromal tumours, Mastocytosis, Multiple myeloma, Multiple sclerosis, Pancreatic cancer, Peripheral T-cell lymphoma, Prostate cancer, Crohn’s disease, Ovarian cancer, and Breast cancer in the 7MM. A detailed picture of Masitinib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Masitinib for potential indications. The Masitinib market report provides insights about Masitinib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Masitinib performance, future market assessments inclusive of the Masitinib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Masitinib sales forecasts, along with factors driving its market.

Masitinib Drug Summary

Masitinib is an orally administered, selective tyrosine kinase inhibitor developed by AB Science, primarily targeting c-Kit, Lyn, Fyn, and PDGFR kinases to modulate mast cell and macrophage/microglia activity, thereby reducing neuroinflammation and immune-mediated damage. Approved as Masivet for treating mast cell tumors in dogs since 2008, it is under investigation for human conditions including amyotrophic lateral sclerosis (ALS), where it slows disease progression by inhibiting microgliosis and extending survival in preclinical models; multiple sclerosis, showing reduced disability progression in progressive forms; severe asthma; Alzheimer's disease; and various cancers like prostate, pancreatic, and melanoma. Its dual mechanism promotes neuroprotection and anti-tumor effects by shifting neuroimmune responses from toxic to protective states, though common side effects include nausea, rash, edema, diarrhea, and hematological issues. The report provides Masitinib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Masitinib Market Report

The report provides insights into:

• A comprehensive product overview including the Masitinib MoA, description, dosage and administration, research and development activities in potential indication like Alzheimer’s disease, Asthma, Colorectal cancer, Gastrointestinal stromal tumours, Mastocytosis, Multiple myeloma, Multiple sclerosis, Pancreatic cancer, Peripheral T-cell lymphoma, Prostate cancer, Crohn’s disease, Ovarian cancer, and Breast cancer.
• Elaborated details on Masitinib regulatory milestones and other development activities have been provided in Masitinib market report.
• The report also highlights Masitinib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Masitinib market report also covers the patents information, generic entry and impact on cost cut.
• The Masitinib market report contains current and forecasted Masitinib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Masitinib market report also features the SWOT analysis with analyst views for Masitinib in potential indications.

Methodology

The Masitinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Masitinib Analytical Perspective by DelveInsight

In-depth Masitinib Market Assessment

This Masitinib sales market forecast report provides a detailed market assessment of Masitinib for potential indication like Alzheimer’s disease, Asthma, Colorectal cancer, Gastrointestinal stromal tumours, Mastocytosis, Multiple myeloma, Multiple sclerosis, Pancreatic cancer, Peripheral T-cell lymphoma, Prostate cancer, Crohn’s disease, Ovarian cancer, and Breast cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Masitinib sales data uptil 2034.

Masitinib Clinical Assessment

The Masitinib market report provides the clinical trials information of Masitinib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Masitinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Masitinib Market Potential & Revenue Forecast

• Projected market size for the Masitinib and its key indications
• Estimated Masitinib sales potential (Masitinib peak sales forecasts)
• Masitinib Pricing strategies and reimbursement landscape

Masitinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Masitinib Market positioning compared to existing treatments
• Masitinib Strengths & weaknesses relative to competitors

Masitinib Regulatory & Commercial Milestones

• Masitinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Masitinib Clinical Differentiation

• Masitinib Efficacy & safety advantages over existing drugs
• Masitinib Unique selling points

Masitinib Market Report Highlights

• In the coming years, the Masitinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Masitinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Masitinib’s dominance.
• Other emerging products for Alzheimer’s disease, Asthma, Colorectal cancer, Gastrointestinal stromal tumours, Mastocytosis, Multiple myeloma, Multiple sclerosis, Pancreatic cancer, Peripheral T-cell lymphoma, Prostate cancer, Crohn’s disease, Ovarian cancer, and Breast cancer are expected to give tough market competition to Masitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Masitinib in potential indications.
• Analyse Masitinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Masitinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Masitinib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Masitinib? How strong is Masitinib’s clinical and commercial performance?
• What is Masitinib’s clinical trial status in each individual indications such as Alzheimer’s disease, Asthma, Colorectal cancer, Gastrointestinal stromal tumours, Mastocytosis, Multiple myeloma, Multiple sclerosis, Pancreatic cancer, Peripheral T-cell lymphoma, Prostate cancer, Crohn’s disease, Ovarian cancer, and Breast cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Masitinib Manufacturers?
• What are the key designations that have been granted to Masitinib for potential indications? How are they going to impact Masitinib’s penetration in various geographies?
• What is the current and forecasted Masitinib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Masitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to Masitinib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Masitinib? What is the duration of therapy and what are the geographical variations in cost per patient?